Skip to content
★ Sign in to follow
HT

Hartley T. Richardson

Executive
Angiotech Pharmaceuticals IncEPIRUS Biopharmaceuticals, Inc.
Total declarations
11
Companies
2
▲ Purchases (8 ops.)
€213k
▼ Sales (0 ops.)
—

Latest filing published 26 Apr 2010 for EPIRUS Biopharmaceuticals, Inc., €349.

Insider track record

Disclosed buys
8
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
8

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Hartley T. Richardson: trading record in brief

This profile gathers the share dealings of Hartley T. Richardson across 2 companies, led by Angiotech Pharmaceuticals Inc and EPIRUS Biopharmaceuticals, Inc. We count 11 filings; the first trade dates from 25 November 2008 and the latest from 22 April 2010.

The open-market record is one-sided, with 8 purchases worth €213k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant. Since January 2010: 2 purchases and no sales on the market.

A typical purchase (the median) is worth €6,434.

The record was last updated on 26 April 2010 with an open-market purchase (€349) in EPIRUS Biopharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Hartley T. Richardson

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations11 total

11 of 11 declarations